GENE EXPRESSION BASE SEQUENCES FOR THERAPEUTIC USE AND DRUGS FOR GENE THERAPY

Abstract: The base sequence for the expression of a therapeutic gene and the medicament for gene therapy are disclosed. There is also disclosed the base sequence for the expression of a therapeutic gene, said sequence being shown in any one of from (a) to (d) and capable of directing the expression of the therapeutic gene specifically to squamous epithelium: (a) the base sequence set forth in SEQ ID NO:1 in the Sequence Listing; (b) the base sequence set forth in SEQ ID NO:18 in the Sequence Listing; (c) the base sequence set forth in SEQ ID NO:17 in the Sequence Listing; and (d) the base sequence set forth in SEQ ID NO:16 in the Sequence Listing. Moreover, there is disclosed the medicament for gene therapy containing a therapeutic gene downstream any of the above-mentioned base sequences, capable of directing the expression of the therapeutic gene specifically to squamous epithelium.

Description: Technical Field This invention relates to base sequences capable of directing the expression of therapeutic genes specifically to squamous epithelia, and to medicaments for gene therapy capable of directing the expression of therapeutic genes specifically to squamous epithelia by the use of the base sequences. Background Art Gene therapy is a therapeutic method by which genes or cells having the introduced genes are administered to the human body for the purpose of the treatment of diseases, and it has drawn attention as a new modality which may replace those currently in use. In 1990 gene therapy was performed on two children who had congenial severe combined immunodeficiency resulting from adenosine deaminase (ADA) deficiency in the United States. Since then over 2,100 cases of gene therapy had been performed around the world till the end of 1996. In this country, the first gene therapy on an ADA deficient patient was initiated in August of 1995. In the research of gene therapy an indispensable technique is to devise an improvement in the safety of medicaments for gene therapy; for example, targeting with which therapeutic genes are only introduced (transferred) into cells that are the subject of treatment not only increases the effectiveness by preventing the administered vector for gene therapy from uselessly diffusing, but also decreases the expression of exogenous genes in unwanted organs or tissues, which then makes it an indispensable technique. Specifically, there are techniques disclosed among others: a HIV vector that is patterned after human immunodeficiency virus (HIV) utilizes the propensity of its envelope protein (existing on the surface) specifically binding to CD4 protein, and can transfer genes only into CD4 positive cells (Shimada T. et al., J. Clin. Invest., 88, 1043, 1991); a recombinant viral vector derived by modifying the envelope of Moloney murine leukemia virus with heregulin can transfer genes only into cells such as lung cancer cells that overexpress epidermal growth factor receptor (EGFR) (Han X.L., et al., Proc. Natl. Acad. Sci. USA, 92, 21, 9747, 1995); a folate conjugated to poly-L-lysine having enhanced affinity to cancer cells which relies on the fact that the folate receptor is overexpressd in cancer cells (Gottschalk S., et al., Gene Ther., 1, 3, 185, 1994; Lee R. J., Hung L., J. Biol. Chem., 271, 14, 8481, 1996). In the meantime, the development of a system capable of directing the expression of a gene specifically to a tissue which is the subject of treatment (tissue specific expression system) is under way. The tissue specific expression system is a technique that focuses on a protein which is only expressed in a certain organ or tissue and that utilizes a gene sequence regulating the expression of a gene such as a promoter and/or an enhancer for the gene that encode this protein. This technique has been disclosed in reviews that are already in public knowledge (e.g., Gabi U. Dachs, et al., Oncology Res., 9, 313, 1997). The tissue-specific promoters/enhancers which are known include the promoter/enhancer for α-fetoprotein (AFP) the specific expression of which can be seen in hepatocellular carcinoma, the promoter region of prostate specific antigen (PSA) the expression of which is increased in prostate cancer, the von Willebrand factor (vWf) and the tie-2/tek promoter both of which are endothelial cell specific, the DF3 promoter the increased expression of which can be seen in breast cancer, the albumin enhancer that is expressed specifically in liver, the tyrosinase promoter that can be specifically expressed in melanoma cells, the myellin basic protein (MBP) promoter that is specific for glioma cells, the osteocalcin promoter that is specific for osteosarcoma cells, and the like. The disease-specific promoters/enhancers include the promoter for carcinoembryonic antigen (CEA) the increased expression of which can be seen in many carcinomas, the HER/neu promoter exhibiting enhanced expression in breast and pancreatic cancers, and the Myc-Max response element that activates transcription by the action of the Myc protein family/Max protein complex which is implicated in cell proliferation, differentiation, and apoptosis. The promoters/enhancers the expression of which is controlled by a wide variety of conditions have also been reported, including the promoter for early growth response-1 gene (Egr-1) upon radiation, tissue type plasminogen activator (t-PA), the GRP78/BiP protein promoter that is induced by tumor-specific conditions such as glucose deprivation and anoxia, hypoxia response element (HRE) exhibiting specific expression under hypoxic conditions, and the like. However, against squamous cell carcinomas such as uterine cervical cancer, skin cancer, head and neck cancer, esophagus cancer, and lung cancer which are reported to account for about 60% of all the carcinomas, there has been no system capable of directing the expression of genes specifically to those carcinomas: there has been no system for carrying out effective gene therapy on these squamous cell carcinomas. Disclosure of the Invention It is an object of this invention to provide a base sequence capable of directing the expression of a therapeutic gene specifically to squamous epithelium. It is also an object of the invention to provide a medicament for gene therapy capable of directing the expression of a therapeutic gene specifically to squamous epithelium by the use of said base sequence. As a result of having pursued diligent investigations on the above-stated problems, the present inventors found novel base sequences capable of directing the expression of therapeutic genes specifically to squamous epithelia. Further, it was found that these novel base sequences had more enhanced capability of gene expression in squamous cell carcinomas such as SKG IIIa cells than in normal squamous epithelia; and this led to the completion of this invention. Specifically, this invention relates to a base sequence for the expression of a therapeutic gene, said sequence capable of directing the expression of the therapeutic gene specifically to squamous epithelium. More specifically, it relates to a base sequence for the expression of a therapeutic gene, said sequence being shown in any one of from (a) to (d) and capable of directing the expression of a therapeutic gene specifically to squamous epithelium: (a) the base sequence set forth in SEQ ID NO:1 in the Sequence Listing; (b) the base sequence set forth in SEQ ID NO:18 in the Sequence Listing; (c) the base sequence set forth in SEQ ID NO:17 in the Sequence Listing; and (d) the base sequence set forth in SEQ ID NO:16 in the Sequence Listing. Further, this invention relates to a medicament for gene therapy having the base sequence for the expression of a therapeutic gene as described above and the therapeutic gene in the downstream thereof, said medicament capable of directing the expression of a therapeutic gene specifically to squamous epithelium. Still further, it encompasses a method for directing the expression of a therapeutic gene to be desirably expressed in certain squamous epithelium by the use of the medicament. Brief Description of the Drawings Fig. 1 is a graph showing the differences in length among inserted fragments in the upstream of SCC-A1 gene for cell species specific expression plasmids according to this invention where the arrow indicates Cap site and the numerals are those based on the base positions in SEQ ID NO:5. Fig. 2 is a graph showing a comparison of the levels of gene expression for cell species specific expression plasmids according to this invention in various cells. Fig. 3 is a graph showing a comparison of the levels of gene expression for cell species specific expression plasmids according to this invention in squamous epithelium. Fig. 4 is a graph showing a comparison of the levels of gene expression for cell species specific expression plasmids according to this invention in squamous cell carcinoma. Fig. 5 is shows a graph showing a comparison of the levels of gene expression for cell species specific expression plasmids according to this invention in ovarian cancer cells. Best Mode for Carrying out the Invention This invention will be described in detail by referring to embodiments. (Base Sequences) The base sequences capable of directing the expression of therapeutic genes specifically to squamous epithelia according to this invention (hereafter referred to as "base sequence(s) of this invention") are consecutive base sequences in the upstream of the structural gene defining the amino acid sequence of squamous cell carcinoma antigen 1 (hereafter referred to as "SCC-A1"). This SSC-A is a protein that is widely known as a tumor marker of squamous cell carcinomas such as uterine cervical cancer, for which SCC-A1 and SCC-A2 exist that are about 95% homologous in gene sequence. These are both located at chromosomal 18q21.3 (S.S. Schneider, et al., Proc. Natl. Acad. Sci. USA, 92, 3147, 1995). Sakaguchi et al. analyzed the SCC-A2 promoter and reported that the strongest transcriptional activity of the gene expression in SKG IIIa (squamous cell carcinoma) cells was obtained when a DNA fragment with a length between the transcriptional start site and 500 bp upstream was used. (Sakaguchi Y., Biochemica et Biophysica Acta, 1444, 111-116, 1999). Shirato et al. determined the serum level of SCC-A in patients with squamous cell carcinoma who had undergone radiotherapy and, consequently, found the SCC-A level in the patients with uterine cervical cancer was correlated with its prognosis; and they reported that the SCC-A protein level would be useful for post treatment monitoring. (Shirato H., et al., Acta Oncologica 32, 6, 663, 1993). The amino acid sequence of SSC-A and the gene sequence encoding the protein are disclosed in Japanese Unexamined Appln. Publn. JP, 4-200387, A. A base sequence of this invention comprises a portion or the whole of the consecutive base sequence of 4324 bp set forth in SEQ ID NO:1 and is a base sequence capable of directing the expression of a therapeutic gene specifically to squamous epithelium. Further, it comprises a portion or the whole of the consecutive base sequence of 1000 bp set forth in SEQ ID NO:18 and is a base sequence capable of directing the expression of a therapeutic gene specifically to squamous epithelium. Further, it comprises a portion or the whole of the consecutive base sequence of 500 bp set forth in SEQ ID NO:17 and is a base sequence capable of directing the expression of a therapeutic gene specifically to squamous epithelium. Still further, it comprises a portion or the whole of the consecutive base sequence of 1250 bp set forth in SEQ ID NO:16 and is a base sequence capable of directing the expression of a therapeutic gene specifically to squamous epithelium. There are no limitations to the method of acquiring the base sequences of this invention. On the basis of the base sequences disclosed herein, methods that are known in the art are preferably applicable. Specifically, they may be prepared by conventional PCR in a buffer containing salts such as magnesium ion with appropriately adjusted concentrations, using the upstream genome region of the SCC-A1 gene as a template and primers that are designed to allow amplification of the targeted region of the template DNA sequence in addition to thermostable DNA polymerase. The thermostable DNA polymerases to be used include Taq DNA polymerase derived from Themus aquaticus, Pfu DNA polymerase derived from Pyrococcus furiosus, thermostable DNA polymerase species of the E. coli recombinant type, and the like. PCR may be carried out on a PCR apparatus available commercially. The base sequence of this invention may be 100 bases or less, because it may comprise a portion of the base sequence set forth in SEQ ID NO:1, SEQ ID NO:18, SEQ ID NO:17, or SEQ ID NO:16. In this case, it is possible to synthesize the base sequences of this invention as nucleic acid compounds. The nucleic acid compounds include oligodeoxyribonucleotides of the natural type, oligodeoxyribonucleotides of the phosphorothioate type, oligodeoxyribonucleotides of the methyl phosphonate type, oligodeoxyribonucleotides of the phoosphoroamidate type, oligodeoxyribonucleotides of the H-phosphonate type, oligodeoxyribonucleotides of the triester type, and the like. In addition to the above-mentioned methods, the synthesis may be carried out according to the phosphamidite method by using a DNA/RNA synthesizer when the nucleic acid synthesis is employed. The phosphoamidite method is a synthetic method based on the following: a phosphoamidite protected with the cyanoethyl group or the like is bound to the 3'-end of a modified deoxyribonucleotide to form a reagent; the reagent is used for condensation to the 5'-end of a different modified deoxyribonucleotide or oligo-modified deoxyribonucleotide. The synthesis is completed in the state where the protected group of sugar hydroxyl moieties at the 5'-end is in linkage at the last cycle. After a synthesized oligomer is cleaved from the support, basic portions and phosphoric acid portions are deprotected to produce crudely purified products. The crudely purified product is purified using a conventional purification method such as ethanol precipitation, or alternatively is purified by a variety of methods such as reverse phase chromatography, ion-exchange chromatography, high pressure liquid chromatography based on the principle of gel filtration chromatography, and super critical chromatography. (Therapeutic Genes) The base sequences of this invention are useful as promoters for directing the expression of therapeutic genes specifically to squamous epithelia. Specifically, a therapeutic gene to be desirably expressed specifically in squamous epithelium can be placed downstream the base sequence of this invention and can be used, for example, by being inserted into a part of the viral genome sequence of a viral vector. The therapeutic genes are not particularly limited insofar as they are those which are expected to have therapeutic effects. Such genes include, for example, XPA-XPG genes, keratin genes, collagen genes, tyrosinase genes, NF1 genes, CTLA4Ig genes, ATM genes, PLP genes, DM20 genes, GCH genes, superoxide dismutase 1 genes, ALD genes, proteolipid protein genes, KCNA1 genes, fibroblast growth factor-3, COMP genes, DSDST genes, fibrillin 1 genes, fibroblast growth factor receptor, monoamine oxidase A or B genes, ADMLX genes, androgen receptor genes, myocardial β-myosin heavy chain genes, myocardial troponin T genes, α-tropomyosin genes, myocardial myosin binding protein C genes, ventricular myosin alkaline light chain genes, ventricular myosin regulating light chain genes, myocardial troponin I genes, LQT1-4 genes, elastin genes, PKD1 and PKD2 genes, phosphatidylinositol class A genes, 1,25-(OH) 2D3 receptor genes, CLCN5 genes, erythrocyte ankyrin genes, CFTR genes, holocarboxylase synthetase genes, ATP8A and ATP8B genes, PAX3 genes, MITF genes, PAX6 genes, crystallin genes, SLC3A1 genes, WAS genes, interleukin 2 receptor γ chain genes, adenosine deaminase genes, OCRL-1 genes, RET genes, endothelin B genes, BLM genes, angiotensinogen genes, angiotensin converting enzyme genes, angiotensin II type I receptor genes, lipoprotein lipase genes, apoC-II genes, low density lipoprotein receptor genes, leptin genes, crowsaw genes, leptin receptor genes, brain glycogen phosphorylase genes, fas genes, fas ligand genes, human leukocyte antigen genes, p53 genes, p15 genes, p16 genes, tyrosinase related protein 1 and tyrosinase related protein 2 genes, VEGF genes, factor VIII genes, factor IX genes, apoE genes, apoB genes, and apoB-100 genes. On or more species of these can be combined for use. The therapeutic genes do not need to be those derived from human if they are expected to have therapeutic effects. Such examples include thymidine kinase genes derived from human herpes simplex virus, viral viroids such as human hepatitis of δ type virus, and ribozymes derived from protozoa ciliate (e.g., Tetrahymena). Among those mentioned above, the representative genes that are expected to be especially efficacious for squamous epithelia, for example, include any genes of from XPA to XPG that are involved in the nucleotide excision repair mechanism with respect to xeroderma pigmentosum, keratin genes or VII type collagen genes with respect to epidermolysis bullosa, thyrosinase genes with respect to thyrosinase negative type albinism, and NF1 genes with respect to neurofibroma type 1. The representative genes that are expected to be especially efficacious for squamous cell carcinomas, for example, include suicide genes such as thymidine kinase genes derived from human herpes simplex virus, genes that encode cancer-specific antigens such as brain glycogen phosphorylase genes, genes that promote the apoptosis of fas gene or the like, genes that enhance the immunogenicity of cancer cells such as human leukocyte antigen genes, cancer-suppressing genes such as p53 gene, genes that act in an antagonistic manner on squamous cell carcinoma (e.g., antisenses and ribozymes). This invention is also applicable in treatment for esthetic purposes, including the inhibition of crease formation, improved humectation, the inhibition of choasma or ephelides formation, and the inhibition of being greasy and acne formation. Specifically, on or more species of the keratin gene or of the collagen gene can be combined for use to inhibit crease formation as well as to improve humectation. To inhibit choasma and ephelides formation, one or more kinds of antisense or ribozyme against a series of enzymes that are involved in melanin formation can be combined for use. The therapeutic genes of this invention also encompass marker genes. For the marker gene, CAT, GUS, β-gal, GFP, EGFP, and the like may be used. A poly A signal may be inserted downstream the therapeutic gene in order to regulate the stability of the expressed therapeutic gene within cell. (Method for Introduction of Therapeutic Genes) A therapeutic gene is introduced into the downstream of the base sequence of this invention and the therapeutic gene is delivered to normal squamous epithelia, squamous cell carcinomas, and the like: such technique is not particularly limited, and, for example, viral vectors may be used, or alternatively non-viral vectors such as synthetic polyamino acids and cationic lipids may be used. When viral vectors are to be used, virus-derived vectors such as a retroviral vector, an adeno-associated vector, a recombinant HIV vector, and a herpes simplex virus can be employed. In the viral vector, the base sequence of this invention is used by being inserted to a part of the viral genome sequence. For example, within the retroviral vector where a leukemia viral vector is used, a recombinant viral genome may be constructed based on such a design that the Long Terminal Repeat (LTR) derived from the leukemia viral vector, the base sequence of this invention, the therapeutic gene, the poly A signal, and LTR are in sequence from the 5'-end of the virus genome. The constructed viral vectors may be packaged into virus particles by methods known in the art. Carriers for non-viral vectors such as synthetic polyamino acids or cationic lipids are to be used: in the case of a synthetic polyamino acid, a carrier comprising an amino acid (e.g., polylysine or serine) as the principle agent may be used, while in the case of a cationic lipid, liposome or the like may be used. In the case of a non-viral vector, the base sequence of this invention, the therapeutic gene and the poly-A signal (both downstream the base sequence) may be inserted to a plasmid for use. (Medicaments for Gene Therapy) The medicaments for gene therapy according to this invention employ the base sequences of this invention described above and are capable of directing the expression of certain therapeutic genes specifically to squamous epithelia. This medicament for gene therapy can be obtained by using the base sequence of this invention as a promoter and introducing the therapeutic gene to the downstream thereof. When the medicament for gene therapy is delivered to the cell by the above-mentioned method, the base sequence of this invention can direct the expression of the therapeutic gene specifically to squamous epithelium. Further, according to this invention, the therapeutic gene can be allowed for its strong expression especially in cancerated squamous epithelium. Such effect is observed with the consecutive sequence of 4324 bases set forth in SEQ NO:1; within this sequence, it is strongly observed with the consecutive sequence of 1000 bases set forth in SEQ NO:18, with the consecutive sequence of 500 bases set forth in SEQ NO:17, and with the consecutive sequence of 250 bases set forth in SEQ NO:16. The therapeutic effects of the medicament for gene therapy according to this invention are utilized in the genetic diseases of all tissues and organs, including squamous epithelia of skin, lung, esophagus, and uterus. Specifically, they are useful in the treatment of genetic skin diseases such as xeroderma pigmentosum, epidermolysis bullosa, ichthyosis, albinism, thyrosinase negative type albinism, and neurofibroma type 1. They are also useful in treatment for esthetic purposes, including the inhibition of crease . formation on the skin, improvement of humectation, the inhibition of choasma or ephelides formation, and the inhibition of being greasy and acne formation. The medicaments for gene therapy according to this invention are useful not only in the treatment of diseases of squamous epithelia, but also in the gene therapy of squamous cell carcinomas; they are especially effective for uterine cervical cancer, skin cancer, head and neck cancer, esphageal cancer, and lung cancer. Methods for administering the medicament for gene therapy according to this invention may employ those by oral administration or parental administration, in addition to those by direct administration to the targeted tissue and organ. The oral administration includes sublingual administration. The parental administration includes injections the administration routes of which are subcutaneous, intramuscular, through vein, arterial, and through drip infusion, suppositories, ointments, and patches. The doses for the medicament for gene therapy according to this invention differ depending on the age, the route of administration and the frequency of administration, and can appropriately be altered. In this case, an effective amount of the medicament for gene therapy according to this invention, a suitable diluent, and a pharmacologically usable carrier form a composition, which is normally administered: the effective amount is in the range of from 1 to 100,000 µg/kg and is administered continuously, or in a divided dose of one to several times daily, or once every few days. When the medicament for gene therapy according to this invention is orally administered, tablets, granules, fine granules, powders, capsules or the like are applicable. These compositions may contain binders, inclusions, excipients, disintegrants, and the like; and they may be in any state of solution for internal use, suspension, emulsion, syrup, and others. When parental administration is used, the composition therefor may contain a stabilizer, a buffer, a preservative, an isotonic agent, and the like, and it is provided in such a state that is an ample for unit dosage, a container for multiple dosages or a tube. The embodiments of this invention will be described concretely by referring to the examples; however, the invention is not to be limited by the following examples. EXAMPLES (EXAMPLE 1) Preparation of membranes for screening Human genome DNA library (EMBL3 SP6/T7, Clonetech #HL2067j, Sau3A I partial digest; Clontech Laboratories Inc.) was diluted with a phage dilution buffer [50 mM Tris-HCl (GIBCO Inc.) containing 100 mM NaCl (Wako Pure Chemical Industries, Ltd.) and 100 mM MgSO 4 (Wako Pure Chemical Industries, Ltd.), pH 7.5, 0.01% gelatin] to give a phage plaque number of 1x10 4 pfu (plaque forming unit) per 100 µl, whereby a plate was prepared for the primary screening such that plaques were uniformly formed thereon. Screening was thus carried out on the total of 1.5x10 5 plaques. The phage preparation containing positive phage clones from the primary screening was diluted with the phage dilution buffer to give a phage plaque number of 3000 pfu per 100 µl, whereby a plate was prepared for the secondary screening such that the isolated plaques were formed thereon. E. coli K802 strain had been grown in 5 ml of LB medium (DIFCO Inc.) one day before it was seeded, and 1 ml of the culture was inoculated in a 5 ml LB medium containing 0.2% maltose and 10 mM MgSO 4 . Then, cultivation was continued until OD600 nm reached the value of 0.6; thereby, E coli was prepared to transfect a phage. The E. coli preparation (300 µl) described above was mixed with a phage dilution and was incubated at 37 °C for 15 minutes. After having been subjected to autoclave, it was added to a LB medium containing 6 ml of 0.75% Bacto-Agar (DIFCO Inc.) incubated at 48 °C and the total amount was added to the LB agar medium. After allowing to stand at room temperature for about 20 minutes, it was incubated at 37 °C overnight. The plate was maintained at 4 °C for 1 hour. Hybond-N+ (Amersham Pharmacia Biotech) was brought into close contact with the LB agar medium, which was allowed to stand for 1 minute. The membrane was air-dried and immersed in a Denature buffer (0.4 M NaOH solution) for 5 minutes, in a Neutralization buffer (0.5 M Tris-HCl solution containing 1 M NaCl, pH 7.5) for 5 minutes, and in 2xSSC for 5 minutes sequentially. The membrane was treated with a UV cross link (UV Strata-linker; Stratagene) and stored in a HYBRIBAG (Cosmo Bio Co., Ltd.). (EXAMPLE 2) Synthesis of DNA probe A DNA probe derived from the SCC-A2 gene that was used for screening was prepared in the following manner. Specifically, cDNA was prepared from mRNA of human uterus cervical cancer cell line HT-III (American Type Cell Collection or ATCC) using M-MLV reverse transcriptase (GIBCO Inc.). PCR primers (SEQ ID Nos.:3 and 4) were used in PCR (GeneAmp PCR system 2400; Perkin Elmer Inc.) to synthesize a 165 bp PCR product. Purification was carried out using a QIAquick PCR purification kit (QIAGEN Inc.) to yield the DNA probe. (EXAMPLE 3) Preparation of 32 P-labeled DNA probe For the labeling of the DNA probe prepared in Example 2 with a radioisotope, a Random primer DNA labeling kit (Takara Shuzo Co., Ltd.) was used to carry out 32 P labeling. Purification was carried out by using a QIAquick nucleotide removal kit (QIAGEN Inc.). (EXAMPLE 4) Screening by plaque hybridization To the membrane prepared in Example 1 was added a prehybridization solution (GIBCO Inc.) at 20 ml per one sheet, which was incubated at 42 °C for 2 hours. After the prehybridization solution was discarded, 20 ml of the hybridization solution (GIBCO Inc.) containing the DNA probe prepared in Example 3 (1x10 7 cpm/ml) was added to the membrane and it was incubated at 42 °C overnight. The membrane was washed three times with 11 of 6xSSC containing 0.1% SDS at 42 °C for 30 minutes, and twice with 11 of 2xSSC containing 0.1% SDS at 65 °C for 30 minutes. The membrane was enclosed in a HYBRIBAG (Cosmo Bio Co., Ltd.) and exposed to an X-ray film (Fuji Film Co., Ltd.) for development at -80 °C for 3 days. The developed film and the plate were superimposed, and then the locations of positive plaques were identified. The locations of positive plaques were cut out and collected, corresponding to their agar areas, to which 500 µl of phage dilution buffer and 5 µl of chloroform (Wako Pure Chemical Industries, Ltd.) was added. After agitation with a Vortex and precipitation of gel fragments upon centrifugation, the supernatant containing positive phage particles was collected. To further isolate positive phages, a secondary screening was carried out according to the methods as described in Examples 1, 3 and the present Example. Thus two kinds of positive phage clone (B612 and C618) were isolated from the isolated plaques. (EXAMPLE 5) Large-scale preparation of phage DNA E. coli K802 strain had been grown one day before it was seeded until OD600 nm reached the value of 0.6. The phage preparation obtained in Example 4 was diluted with a phage dilution buffer to adjust B612 and C618 to 10 10 pfu/ml, respectively. After cultivation at 37 °C, chloroform and NaCl were added to the phage preparation, which was shaken at 37 °C for 30 minutes. Centrifugation at 5000xg for 30 minutes was carried out and a supernatant containing phages was collected. Extraction of the phage DNAs was performed in the following manner. After addition of 100 g of polyethylene glycol (Wako Pure Chemical Industries, Ltd.) and precipitation overnight, super-centrifugation was conducted at 35000 rpm for 18 hours by using 0.75 g/ml of CsCl (GIBCO Inc.). Then, dialysis was carried out overnight against a SM buffer [50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10 mM MgSO 4 , 0.01% gelatin]. After this was subjected to shaking with a phenol solution containing 0.02% SDS for 1 hour, purification was carried out by dialysis with TE buffer. This resulted in the collection of 800 µg of the phage DNA for B612 as well as in the collection of 910 µg of the phage DNA for C618. (EXAMPLE 6) Sequencing of the upstream sequence of SCC-A gene In both B612 and C618 clones, sequencing was carried out on the upstream of the sequence set forth in SEQ ID NO:2. This resulted in the DNA sequence set forth in SEQ ID NO:5 from C618 and the DNA sequence set forth in SEQ ID NO:6 from B612. The results of homology search showed that the 3'-end region of SEQ ID NO:5 was highly homologous to the exon 1 and exon 2 sequences of human squamous cell carcinoma antigen 1 (SCC-A1) and that the 3'-end region of SEQ ID NO:6 was highly homologous to the exon 1 and exon 2 sequences of human squamous cell carcinoma antigen 1 (SCC-A2). This revealed that SEQ ID NO:5 was a sequence containing the upstream of the SCC-A1 genome gene and a portion of the SCC-A1 gene and that SEQ ID NO:6 was a sequence containing the upstream of the SCC-A2 genome gene and a portion of the SCC-A2 gene. (EXAMPLE 7) Determination of Cap site Total mRNA was prepared from SKG IIIa cells (Human Science Research Resource Bank Co., Ltd.; formerly Japan Cancer Research Resource Bank Co., Ltd.) by using ISOGEN (Nippon Gene Co., Ltd.). Reverse transcription employed a SMART PCR cDNA SYNTHESIS kit (Clontech Laboratories Inc.) and SuperScript II RNase H reverse transcriptase (GIBCO Inc.). This produced cDNA where the sequence set forth in SEQ ID NO: 7 was linked to its 5'-end. This reverse transcript was used as a template in PCR, which was carried out using PCR primers of SEQ ID NO:8 (appended to the SMART PCR cDNA SYNTHESIS kit) and SEQ ID NO:9 (Sawady Technology Co., Ltd.). The mixed solution after reaction was subjected to 0.8% agarose electrophoresis and the PCR product amplified specifically was collected as a gel fragment. The gel was extracted using a QIAquick Gel extraction kit (QIAGEN Inc.). The purified PCR product was mixed with 0.1 µg of Bluescript II T-vector (Toyobo Co., Ltd.) and ligation was carried out by using T4 DNA Ligase (GIBCO Inc.) at 4 °C overnight. Competent E. coli XLI-blue (Takara Shuzo Co., Ltd.), 200 µl, was dissolved in ice, and it was added to the ligation reaction solution described above and maintained for 30 minutes. After incubation at 42 °C for 60 seconds, it was again placed in ice for 5 minutes. To this was added 800 µl of a SOC medium (GIBCO Inc.) and incubated at 37 °C for 1 hour. Cells (100 µl) were inoculated in a LB agar medium containing 50 µg/ml ampicilin (Wako Pure Chemical Industries, Co., Ltd.) and incubated at 37 °C overnight. Single colonies (five clones) were selected and were added to a LB liquid medium containing 50 µg/ml ampicilin, which was further incubated at 37 °C overnight. The five clone plasmids that had been picked up were purified with a QIAGEN plasmid MINI kit (QIAGEN Inc.). The upstream sequence of the five purified clones was identified with a DNA sequencer Type 310 (ABI Inc.). The result revealed that the Cap site of the SCC-A1 gene was the 4296th base in SEQ ID NO:5. (EXAMPLE 8) Construction (I) of expression plasmids The phage DNA (C618) obtained in Example 5 was used as a template in PCR, which was carried out using combinations of PCR primers shown in Table 1 to prepare five DNA fragments in the upstream of the SCC-A1 gene with varying lengths (set forth in SEQ ID Nos.:16-18). The mixed solutions after reaction were subjected to 0.8% agarose gel electrophoresis and the PCR products amplified specifically were collected. The gels were extracted using a QIAquick Gel extraction kit (QIAGEN Inc.). The results are collectively shown in Table 1. PCR Products DNA fragment upstream primer downstream primer the length of PCR product (bp) SEQ ID NO:16 SEQ ID NO:10 SEQ ID NO:15 250 SEQ ID NO:17 SEQ ID NO:11 SEQ ID NO:15 500 SEQ ID NO:18 SEQ ID NO:12 SEQ ID NO:15 1000 SEQ ID NO:19 SEQ ID NO:13 SEQ ID NO:15 1997 SEQ ID NO:20 SEQ ID NO:14 SEQ ID NO:15 3680 Basic vector (Nippon Gene Co., Ltd.), 0.1 µg, was subjected to restriction enzyme treatment by M1u I (Takara Shuzo Co., Ltd.) and Bg1 II (Takara Shuzo Co., Ltd.). The vector was mixed with the respective PCR products and ligation was carried out at 16 °C overnight by using a DNA ligation kit (Takara Shuzo Co., Ltd.). By using the technique shown in Example 7, transformation was carried out and the plasmids were purified with a QIAGEN plasmid MINI kit. The gene sequences of the plasmids into which the sequences set forth SEQ ID Nos.:16-20 had been inserted were identified with a DNA sequencer Type 310 (ABI Inc.). Following the aforementioned manipulations, the expression vectors having the upstream of the SCC-A1 gene with varying lengths (SEQ ID Nos.:16-18 as shown in Fig. 1) were prepared. (EXAMPLE 9) Gene expression test I Normal human epidermal keratinocytes (normal squamous epithelia) (Dainippon Pharmaceutical Co., Ltd.), SKG IIIa cells (squamous cell carcinoma), and ovarian cancer cells (SKOV3) (ATCC), which are non-squamous cell carcinoma cells, were inoculated in 12-well plates at 1.0x10 6 cells/well and grown overnight. Five kinds of plasmid having SEQ ID Nos.: 16-20, a control vector having a SV40 promoter as positive control (Nippon Gene Co., Ltd.), and a basic vector having no promoter sequence as negative control were used in the respective tests. To each plasmid (1 µg) was added 6 µg of DOTAP liposomal transfection reagent solution (Boheringer-Mannheim Inc.), and it was allowed to stand at room temperature for 15 minutes to prepare a mixed transfection solution. For the addition group of epidermal keratinocytes, the mixed solution was added to 1 ml of a serum-free medium for normal human epidermal keratinocytes (Dainippon Pharmaceutical Co., Ltd.), while for the addition group of SKG IIIa cells and SKOV3 cells the mixed solution was added to 1 ml of an RPMI 1649 medium (GIBCO Inc.) containing 10% FCS (GIBCO Inc.). These were added to the 12-well plates on which the respective cells had been inoculated, and they were incubated at 37 °C under 5% CO 2 atmosphere. Six hours later the respective growth media were exchanged, and further incubated at 37°C under 5% CO 2 atmosphere for 48 hours. Forty eight hours later, a PicaGene Cell Culture Lysis reagent Luc (Nippon Gene Co., Ltd.) that had been diluted with PBS(-) solution was added at 200 µl per well to lyse the cells. The luciferase activity was determined using a PicaGene Luminescence Kit (Nippon Gene Co., Ltd.). Lumicounter 700 (Microtech Inc.) was used as a luminometer. The results are shown in Fig. 2. With respect to the five kinds of plasmid having the sequences set forth in SEQ ID Nos.:16-20, an increase in the luciferase activity was observed with epidermal keratinocytes and with SKG IIIa cells. On the other hand, almost no luciferase activity was detected in SKOV3 cells: at the same level as that of the basic vector having no promoter. With respect to the control vector having a SV40 promoter, the same high level of luciferase activity was detected in all the cells with no cell species specificity. This revealed that the five kinds of plasmid having SEQ ID Nos.:16-20 had the gene expression activity specific for squamous epithelium. Particularly, it was revealed that among the five kinds of plasmid having SEQ ID Nos.:16-20, the plasmids having the sequences set forth in SEQ ID Nos.:16-18 had strong gene expression activity. Further, it was found that the plasmid having the sequence set forth in SEQ ID NO:17 exhibited the strongest gene expression activity. (EXAMPLE 10) Construction (II) of expression plasmids To further investigate the specificity of SEQ ID NO: 17 which exhibited the strongest gene expression activity in Example 9, DNA fragments having the sequences set forth in SEQ ID Nos.:24-26 were prepared from the upstream of the SCC-A1 gene (SEQ ID NO:5), respectively, and the expression plasmids were constructed. Specifically, the expression plasmids were constructed by using the combinations of primers as shown in Table 2 according to the method similar to that of Example 8. Likewise, the upstream of the SCC-A2 gene (SEQ ID NO:6) was used as the template to construct DNA fragments (SEQ ID NO:27-32) having the same lengths as those of the DNA fragments having the sequences set forth in SEQ ID Nos.:16-18 and SEQ ID Nos.:24-26. The results are shown in Tables 2 and 3, respectively. PCR Products (derived from the upstream of the SCC-A1 gene) DNA fragment upstream primer downstream primer the length of PCR product (bp) SEQ ID NO 24 SEQ ID NO:21 SEQ ID NO:15 125 SEQ ID NO:25 SEQ ID NO:22 SEQ ID NO:15 625 SEQ ID NO:26 SEQ ID NO:23 SEQ ID NO:15 750 PCR Products(derived from the upstream of the SCC-A2 gene) DNA fragment upstream primer downstream primer the length of PCR product (bp) SEQ ID NO:27 SEQ ID NO:21 SEQ ID NO:15 125 SEQ ID NO:28 SEQ ID NO:11 SEQ ID NO:15 250 SEQ ID NO:29 SEQ ID NO:10 SEQ ID NO:15 500 SEQ ID NO:30 SEQ ID NO:22 SEQ ID NO:15 625 SEQ ID NO:31 SEQ ID NO:23 SEQ ID NO:15 750 SEQ ID NO:32 SEQ ID NO:12 SEQ ID NO:15 1001 (EXAMPLE 11) Gene expression test II The expression plasmids having DNA fragments (SEQ ID NOs.:16-18) derived from the upstream of the SCC-A1 gene that had been prepared in Example 9, as well as the expression plasmids having DNA fragments (SEQ ID NOs.:24-26) derived from the upstream of the SCC-A1 gene and the expression plasmids having DNA fragments (SEQ ID NOs.:27-32) derived from the upstream of the SCC-A2 gene that had been prepared in Example 10 were determined for their gene expression activity. The results are shown in Figs. 3-5. Fig. 3 shows the gene expression activity of each expression plasmids in epidermal keratinocytes; Fig. 4 shows the gene expression activity of each expression plasmid in SKG IIIa cells; and Fig. 5 shows the gene expression activity of each expression plasmid in ovarian cancer cells, respectively. With respect to the six kinds of plasmid having the DNA fragments derived from the upstream of the SCC-A1 gene (having the sequences set forth in SEQ ID NOs.:16-18 and 24-26) and the six kinds of plasmid having the DNA fragments derived from the upstream of the SCC-A2 gene (having the sequences set forth in SEQ ID NOs.:27-32), almost no luciferase activity was detected invariably in SKOV3 cells: at the same level as that of the basic vector having no promoter (Fig. 5). With respect to all the expression plasmids described above, an increase in the luciferase activity was observed with epidermal keratinocytes and with SKG IIIa cells as compared to the basic vector (Figs. 3 and 4). Further, with respect to the expression plasmid of SEQ ID NO:17, the same high level of luciferase activity as that of the control vector having a SV40 promoter with no demonstrated cell species specificity was detected in SKG IIIa cells. Thus, it was found that the twelve kinds of plasmid having the DNA fragments derived from the upstream of the SCC-A1 gene and from the upstream of the SCC-A2 gene all posses cell species specific, particularly squamous epithelium specific, gene expression activity. When both expression plasmid groups are compared, the former expression group (i.e., that which contain the base sequences derived from the upstream of the SCC-A1 gene) exhibited higher gene expression activity. It was further confirmed that the plasmid bearing a DNA fragment insert derived from the upstream of the SCC-A1 gene (having the sequence set forth SEQ ID NO:17) exhibits the strongest gene expression activity as compared to the other plasmids bearing DNA fragments other than that derived from the upstream of the SCC-A1 gene and to all the plasmids bearing DNA fragments derived from the upstream of the SCC-A2 gene. Industrial Applicability The base sequences for the expression of therapeutic genes according to this invention are those upstream the SCC-A gene and have the promoter function of directing the expression of certain genes specifically to squamous epithelia. According to this invention, the therapeutic genes can be specifically expressed in squamous epithelia by introducing the therapeutic genes to the downstream of such base sequences as mentioned above. Moreover, according to this invention, the medicaments for gene therapy where therapeutic genes are introduced to the downstream of the above-mentioned base sequences can be obtained that are capable of directing the expression of the therapeutic genes specifically to squamous epithelia. SEQUENCE LISTING <110> Hisamitsu Pharmaceutical Co., Inc. <120> Base sequences for expression of genes for treatment and medicinal agents for gene therapy <130> EP22578-03138/GRI <140> PCT/JP00/02102 <141> 2000-03-31 <150> JP 11/096358 <151> 1999-04-02 <160> 32 <170> Patent In Ver. 2.1 <210> 1 <211> 4324 <212> DNA <213> Homo sapiens <400> 1 <210> 2 <211> 165 <212> DNA <213> Homo sapiens <220> <223> Probe <400> 2 <210> 3 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 3 <210> 4 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 4 <210> 5 <211> 5279 <212> DNA <213> Homo sapiens <220> <223> Template <400> 5 <210> 6 <211> 4384 <212> DNA <213> Artificial Sequence <220> <223> Template <400> 6 <210> 7 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 7 <210> 8 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 8 <210> 9 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 9 <210> 10 <211> 29 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 10 <210> 11 <211> 29 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 11 <210> 12 <211> 29 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 12 <210> 13 <211> 29 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 13 <210> 14 <211> 29 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 14 <210> 15 <211> 29 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 15 <210> 16 <211> 250 <212> DNA <213> Homo sapiens <400> 16 <210> 17 <211> 500 <212> DNA <213> Homo sapiens <400> 17 <210> 18 <211> 1000 <212> DNA <213> homo sapiens <400> 18 <210> 19 <211> 1997 <212> DNA <213> Homo sapiens <400> 19 <210> 20 <211> 3680 <212> DNA <213> Homo sapiens <400> 20 <210> 21 <211> 29 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 21 <210> 22 <211> 29 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 22 <210> 23 <211> 29 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 23 <210> 24 <211> 125 <212> DNA <213> Homo sapiens <400> 24 <210> 25 <211> 625 <212> DNA <213> Homo sapiens <400> 25 <210> 26 <211> 750 <212> DNA <213> Homo sapiens <400> 26 <210> 27 <211> 125 <212> DNA <213> Homo sapiens <400> 27 <210> 28 <211> 250 <212> DNA <213> Homo sapiens <400> 28 <210> 29 <211> 500 <212> DNA <213> Homo sapiens <400> 29 <210> 30 <211> 625 <212> DNA <213> Homo sapiens <400> 30 <210> 31 <211> 750 <212> DNA <213> Homo sapiens <400> 31 <210> 32 <211> 1001 <212> DNA <213> Homo sapiens <400> 32

Claims: A base sequence for the expression of a therapeutic gene, said sequence being shown in any of from (a) to (d) and capable of directing the expression of the therapeutic gene specifically to squamous epithelium: (a) the base sequence set forth in SEQ ID NO:1 in the Sequence Listing; (b) the base sequence set forth in SEQ ID NO:18 in the Sequence Listing; (c) the base sequence set forth in SEQ ID NO:17 in the Sequence Listing; (d) the base sequence set forth in SEQ ID NO:16 in the Sequence Listing. A medicament for gene therapy comprising the base sequence according to claim 1 and a therapeutic gene downstream thereof, said medicament being capable of directing the expression of the therapeutic gene specifically to squamous epithelium.

Inventors: AKIYAMA KATSUHIKO, GOTO TAKESHI, HAMADA KATSUYUKI, YUDA KAZUHIRO, AKIYAMA, KATSUHIKO, GOTO, TAKESHI, HAMADA, KATSUYUKI, YUDA, KAZUHIRO, AKIYAMA, Katsuhiko, Hisamitsu Pharmaceutical Co.,, GOTO, Takeshi, Hisamitsu Pharmaceutical Co.,, YUDA, Kazuhiro, Hisamitsu Pharmaceutical Co.,
Applicants: HISAMITSU PHARMACEUTICAL CO, HISAMITSU PHARMACEUTICAL CO. INC.
Application year: 2000
Main classification: C12N15
IPC codes: C07K14, C12N15, A61K38, A61K48